← Back to screener

ABEONA THERAPEUTICS INC. ABEO

Rank #2518 · Nasdaq · $0.2B market cap
⚠ Going-concern flag — the auditor (Deloitte & Touche LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.
Score
9.2
P/E
-3.9
P/B
16.72
ROE
-429.9%
Op. Margin
-1103.3%
Debt Ratio
438%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -3.9x, P/B 16.72x. Ranks in the top 89% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -429.9%. Ranks in the top 98% of the universe.

Safety ★☆☆☆☆
Weak

Debt ratio 438%. Ranks in the top 78% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★★★★
Excellent

Revenue growth of 66.3% year over year. Ranks in the top 6% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$-0.0B$-0.0B$-0.0B–-142
2012–$-0.0B$-0.0B$-0.0B–-121
2013–$-0.0B$-0.0B$-0.0B–-110
2014–$-0.0B$0.0B$-0.0B–-90
2015–$-0.0B$-0.0B$-0.0B–-80
2016–$-0.0B$-0.0B$0.0B–256
2017–$-0.0B$-0.0B$0.1B–18
2018$0.0B$-0.0B$-0.0B$0.1B-2686.313
2019$0.0B$-0.0B$-0.0B$0.1B-3325.741
2020$0.0B$-0.1B$-0.1B$0.1B-770.934
2021$0.0B$-0.1B$-0.1B$0.2B-814.227
2022$0.0B$-0.1B$-0.1B$0.1B-2994.536
2023$0.0B$-0.1B$-0.0B$0.0B-3600.888
2024$0.0B$-0.0B$-0.1B$0.0B-1346.7184
2025$0.0B$-0.1B$-0.1B$0.0B-1103.3438

← See the full screener